Why poor target validation is costing pharmaceutical businesses millions

It has been well documented that only 1 out of 10 compounds that enter clinical trials makes it to market¹. That is an astonishing 90%...

• Point of View

Watch Causaly’s panel discussion from Discovery Europe

On June 9th – 10th 2022, over 400 pharma leaders came to Berlin to take part in Discovery Europe...

• General

Webinar - Knowledge discovery reimagined: finding new hypotheses with Causaly Cloud

It is well recognized among scientists that target selection can improve clinical trial success rates (1). Being able to stay up to date...

• use case

How AI is redefining hypothesis generation in pharma research

It is widely recognized that the Scientific Method is fundamental for discovering new medicines. We’re all familiar with the process: a...

• Point of View